Gain Therapeutics, Inc. (GANX) – What Are Analysts Thinking About This Stock?

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned an average rating of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $7.67.

Several brokerages recently weighed in on GANX. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, October 5th. BTIG Research reiterated a “buy” rating and issued a $5.00 price target on shares of Gain Therapeutics in a research report on Monday, October 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Friday, September 4th.

Gain Therapeutics Stock Performance

GANX opened at $1.13 on Thursday. The business has a 50 day moving average price of $1.60 and a two-hundred day moving average price of $1.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36. The company has a market capitalization of $49.32 million, a price-to-earnings ratio of -2.26 and a beta of 0.19. Gain Therapeutics has a 1-year low of $1.11 and a 1-year high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. Research analysts predict that Gain Therapeutics will post -0.50 EPS for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

Several hedge funds have recently made changes to their positions in the business. BOKF NA acquired a new stake in shares of Gain Therapeutics during the third quarter worth $35,000. Squarepoint Ops LLC purchased a new stake in shares of Gain Therapeutics during the second quarter valued at $277,000. HighTower Advisors LLC acquired a new position in shares of Gain Therapeutics in the 2nd quarter valued at $35,000. HB Wealth Management LLC acquired a new position in shares of Gain Therapeutics in the 2nd quarter valued at $26,000. Finally, Two Sigma Securities LLC purchased a new position in Gain Therapeutics in the 2nd quarter worth about $26,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms.

Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.